Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Finished Goods (2021 - 2023)

Kiniksa Pharmaceuticals International's Finished Goods history spans 3 years, with the latest figure at $12.9 million for Q4 2023.

  • For Q4 2023, Finished Goods fell 15.85% year-over-year to $12.9 million; the TTM value through Dec 2023 reached $12.9 million, down 15.85%, while the annual FY2023 figure was $12.9 million, 15.85% down from the prior year.
  • Finished Goods reached $12.9 million in Q4 2023 per KNSA's latest filing, up from $12.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $19.9 million in Q2 2022 to a low of $1.4 million in Q3 2021.
  • Average Finished Goods over 3 years is $10.4 million, with a median of $12.5 million recorded in 2023.
  • Peak YoY movement for Finished Goods: surged 927.48% in 2022, then decreased 24.22% in 2023.
  • A 3-year view of Finished Goods shows it stood at $3.7 million in 2021, then skyrocketed by 315.97% to $15.3 million in 2022, then fell by 15.85% to $12.9 million in 2023.
  • Per Business Quant, the three most recent readings for KNSA's Finished Goods are $12.9 million (Q4 2023), $12.2 million (Q3 2023), and $17.3 million (Q2 2023).